title: The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth.
abstract: It has been demonstrated that quercetin (3,3',4',5,7-pentahydroxyflavone) inhibits the growth of several cancer cell lines and that the antiproliferative activity of this substance is probably mediated through a binding interaction with type II estrogen binding sites (type II EBS). The effect of quercetin and cytosine arabinoside (Ara-C) alone or in combination, was tested on HL-60 cell growth. Quercetin significantly synergized the inhibitory activity of Ara-C on HL-60 cell growth while rutin, the 3-rhamnosylglucoside of quercetin, neither competed with [3H]estradiol for type II EBS nor was effective alone or in combination with Ara-C. Based on these results, we studied by a clonogenic assay the effect of quercetin and Ara-C alone and in combination on colony formation by human leukemic cells (CFU-L). In all cases both drugs exhibited a dose-related inhibition of CFU-L in a range of concentrations between 10 nM and 10 microM and 0.01 nM and 10 microM for quercetin and Ara-C, respectively. The combination of the two drugs resulted in a synergistic inhibitory activity on CFU-L. Considering that plasma concentrations of quercetin effective in vitro were obtained in vivo without any apparent side effects, we conclude that this report represents further experimental evidence that quercetin could be used in the treatment of acute leukemias.
authors.affiliation: Istituti di Semeiotica Medica, Università Cattolica del Sacro Cuore, Roma, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Teofili
authors.forename: L
authors.initials: L
authors.lastname: Pierelli
authors.forename: M S
authors.initials: MS
authors.lastname: Iovino
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: G
authors.initials: G
authors.lastname: Scambia
authors.forename: R
authors.initials: R
authors.lastname: De Vincenzo
authors.forename: P
authors.initials: P
authors.lastname: Benedetti-Panici
authors.forename: G
authors.initials: G
authors.lastname: Menichella
authors.forename: E
authors.initials: E
authors.lastname: Macrì
authors.forename: M
authors.initials: M
authors.lastname: Piantelli
mesh_terms: D000208:Acute Disease; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000378:metabolism / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism / Q000473:pathology*; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000378:metabolism / Q000473:pathology*; D011794:Quercetin / Q000378:metabolism / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014410:Tumor Stem Cell Assay
chemical_list: D011960:Receptors, Estrogen; D003561:Cytarabine; D011794:Quercetin